title: Accumulated endogenous NOS inhibitors, decreased NOS activity, and impaired cavernosal relaxation with ischemia.
abstract: We examined whether endogenous inhibitors of nitric oxide (NO) synthesis are involved in the impaired cavernosal relaxation with ischemia in rabbits. Two weeks after cavernosal ischemia caused by partial vessel occlusion, endothelium-dependent and electrical field stimulation (EFS)-induced neurogenic NO-mediated relaxations, but not sodium nitroprusside (SNP)-induced relaxation, were significantly impaired in the isolated corpus cavernosum. The Ca(2+)-dependent NO synthase (NOS) activity and the basal and stimulated cGMP productions with carbachol or EFS were significantly decreased after ischemia. Supplementation of excess L-arginine partially recovered both of the impaired relaxations. The contents of N(G)-monomethyl-L-arginine (L-NMMA) and asymmetric N(G), N(G)-dimethyl-L-arginine (ADMA) but not L-arginine and symmetric N(G),N'(G)-dimethyl-L-arginine (SDMA) were increased in the cavernosal tissues after ischemia. Authentic L-NMMA and ADMA but not SDMA concentration dependently inhibited both relaxations without affecting the relaxation produced by SNP in the control. Excess L-arginine abolished the inhibition with L-NMMA and ADMA. These results suggest that the impaired NO-mediated cavernosal relaxations after ischemia are closely related to the decreased NOS activity and the increased accumulation of L-NMMA and ADMA.
authors: Department of Urology and Reproductive Medicine, Institute of Biomaterials and Bioengineering, Graduate School, Tokyo Medical and Dental University, Tokyo 101 - 0062, Japan.
authors: Hitoshi
authors: H
authors: Masuda
authors: Toshihiko
authors: T
authors: Tsujii
authors: Tetsuo
authors: T
authors: Okuno
authors: Kazunori
authors: K
authors: Kihara
authors: Moritaka
authors: M
authors: Goto
authors: Hiroshi
authors: H
authors: Azuma
mesh_terms: D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002217:Carbachol / Q000494:pharmacology; D018679:Cholinergic Agonists / Q000494:pharmacology; D006152:Cyclic GMP / Q000096:biosynthesis; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007083:Iliac Artery / Q000503:physiopathology; D018783:Impotence, Vasculogenic / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D066298:In Vitro Techniques; D007511:Ischemia / Q000150:complications / Q000503:physiopathology*; D008297:Male; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010413:Penis / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology*; D011817:Rabbits; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology; D019323:omega-N-Methylarginine / Q000378:metabolism / Q000494:pharmacology
chemical_list: D018679:Cholinergic Agonists; D004791:Enzyme Inhibitors; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D019323:omega-N-Methylarginine; C018524:N,N-dimethylarginine; D002217:Carbachol; D001120:Arginine; D019001:Nitric Oxide Synthase; D006152:Cyclic GMP; D002118:Calcium